Skip to content

Efficacy of implementation of the Goal-directed Medication review Electronic Decision Support System (G-MEDSS) into Home Medicines Review (HMR) to deprescribe medications in older adults

Implementation of the Goal-directed Medication review Electronic Decision Support System (G-MEDSS) into Home Medicines Review (HMR) to deprescribe medications in older adults - a cluster randomised controlled trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12617000895381
Enrollment
201
Registered
2017-06-19
Start date
2017-09-21
Completion date
2018-11-28
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Background: This project is a cluster randomised clinical trial investigating the implementation of a computerised clinical decision support system into the Home Medicines Review (HMR) service to deprescribe inappropriate medications in older adults. Older Australians aged 65 years or over are commonly prescribed multiple medications and the doctor may arrange for a HMR. This service is a way for the pharmacist and doctor to help manage medications in the home. This project is investigating to see whether adding a computerised system into HMR will help to use medicines effectively and to avoid any unwanted side effects. Hypothesis: We hypothesise that the combination of pharmacist-led medication review (HMR) and a computerised clinical decision support system intervention that incorporates validated deprescribing tools and guides (e.g. drug burden index (DBI), patients attitudes towards deprescribing (PATD) and Goals of Care, i.e. G-MEDSS) may reduce the proportion of older adults using anticholinergic and sedative medications, and improve clinical outcomes in community-dwelling older adults. Purpose: This study aims to test the efficacy of the addition of GMEDSS in HMR to: • Reduce anticholinergic and sedative medication use (as measured by the DBI) in patients who are exposed to these medications • Measure the effect of these medication changes on clinical and functional outcomes (adherence, cognitive and physical function, falls, institutionalisation, mortality)

Interventions

The Goal-directed Medication review Electronic Decision Support System (G-MEDSS) (accessible from gmedss.com) is a validated electronic platform that has been designed to provide clinical decision support for healthcare practitioners when completing a medication review for their older patients, to tailor care to meet their goals and preferences. The G-MEDSS is designed to produce patient-specific deprescribing reports for a patient’s GP. The G-MEDSS contains three tools: 1) The Goals of Care M

The Goal-directed Medication review Electronic Decision Support System (G-MEDSS) (accessible from gmedss.com) is a validated electronic platform that has been designed to provide clinical decision support for healthcare practitioners when completing a medication review for their older patients, to tailor care to meet their goals and preferences. The G-MEDSS is designed to produce patient-specific deprescribing reports for a patient’s GP. The G-MEDSS contains three tools: 1) The Goals of Care Management tool allows the patient’s goals of care to be identified and aligned with their medication strategies. 2) The Drug Burden Index Calculator© is a validated tool that identifies medications with anticholinergic and sedative effects (measured by the DBI) and provides information and recommendations for physicians. 3) The revised Patient’s Attitudes Towards Deprescribing questionnaire (rPATD) was developed and validated to explore people’s attitudes, beliefs, and experiences regarding the number of medications that they are taking, and how they would feel about cessation of one or more of their medications. The G-MEDSS deprescribing report for an individual patient includes the patient’s global goal of care, a summary of the patient’s current medications, the patient’s DBI score and information about interpreting the DBI, information about the rPATD, and a summary of the patient’s responses to the rPATD. The G-MEDSS system also allows accredited pharmacists to enter medication recommendations and actions on the G-MEDSS reports to allow for the GP to comment on deprescribing recommendations. The G-MEDSS system also allows for a patient summary report (or carer’s summary report) to be produced that can be provided to patients or carers at the time of the Home Medicines Review (HMR). Accredited pharmacists are specially trained pharmacists who are able to conduct medication management reviews (such as a HMR) for patients, under the referral of a general practitioner. Accredited Pharmacists are usually registered with the Australian Association of Consultant Pharmacy or the Society of Hospital Pharmacy. The HMR service is an Australian government-funded community-based collaborative service between the patient, general practitioner (GP) and accredited pharmacist. As part of the service, an accredited pharmacist receives a referral for a patient from the GP (either directly or through the patient’s community pharmacy), conducts an interview with the patient (usually in the home) to gain a comprehensive medication profile, and documents medication review findings and recommendations in a report for the GP, which can then be used to formulate the patient’s medication management plan. Accredited Pharmacists in the intervention group in this study will produce G-MEDSS reports for their HMR patients to send together with the HMR report to the patient’s GP. This will be done once at baseline.

Sponsors

University of Sydney
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

As this is a cluster randomised study, there are two tiers of recruitment: a) Australian registered accredited pharmacists who have conducted at least 24 HMRs in the last 12 months, and conduct 2-20 HMRs per month, will be eligible to participate in this study. b) eligibility for individual patients (with and without dementia) include: aged 65 years and older who can speak English, are eligible for a HMR (according to eligibility listed on http://6cpa.com.au/medication-management-programmes/home-medicines-review/), and are able to provide informed written consent (patient or carer).

Exclusion criteria

Pharmacists that are not accredited to conduct medication reviews, or conduct fewer than 24/year. Patients <65 years old

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 19, 2026